Saridegib also known as IPI-926 is an experimental drug candidate undergoing clinical trials for the treatment of various types of cancer, including hard to treat hematologic malignancies such as myelofibrosis and ligand-dependant tumors such as chondrosarcoma. IPI-926 exhibits its pharmacological effect by inhibition of the G protein-coupled receptor smoothened, a component of the hedgehog signaling pathway. Chemically, it is a semi-synthetic derivative of the alkaloid cyclopamine. The process begins with cyclopamine extracted from harvested Veratrum californicum which is taken through a series of alterations resulting in an analogue of the natural product cyclopamine, making IPI-926 the only compound in development/testing that is not fully synthetic.

CAS：1037210-93-7
中文别名：
英文别名：UNII-JT96FPU35X;IP9 FREE BASE;IPI 926;SARIDEGIB;FIN-5;
分子式：C29H48N2O3S
分子量：504.768
精确质量：504.339
Psa：75.81
Logp：6.8293

UNII：JT96FPU35X

储存条件：2-8℃